{"@id":"https://bioecon.ru/technology/conjugate-vaccines-polysaccharide/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/conjugate-vaccines-polysaccharide/","json":"https://en.bioecon.ru/api/v1/technology/conjugate-vaccines-polysaccharide/index.json"},"id":"conjugate-vaccines-polysaccharide","industries":["pharma","advanced-therapies","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/advanced-therapies/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/meihua-biological/","https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/pallas-biotech/","https://bioecon.ru/companies/loopworm/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/brevel/","https://bioecon.ru/companies/unibio/","https://bioecon.ru/companies/amai-proteins/"]},"maturity":9,"name":"Polysaccharide-Protein Conjugate Vaccines (Pneumococcal, Meningococcal and Hib CRM197 Platforms)","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-15","entity":"who.int","kind":"official","urls":["https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/pneumococcal-disease"]},{"date":"2026-11-15","entity":"sciencedirect.com","kind":"research","urls":["https://doi.org/10.1016/j.vaccine.2021.05.093"]}],"stages":[{"n":1,"title":null},{"n":2,"title":null},{"n":3,"title":null},{"n":4,"title":null},{"n":5,"title":null}],"summary":"Multivalent conjugate vaccines covalently linking purified bacterial capsular polysaccharides to immunogenic carrier proteins (CRM197 or tetanus toxoid) to convert T-cell-independent antigens into T-dependent responses inducing high-affinity IgG memory in infants under 2 years.","url":"/technology/conjugate-vaccines-polysaccharide/","verified":"2026-11-15"}